质母细胞瘤中耐药性:从化疗到免疫治疗
Sachin Sharma1, Oksana Chepurna1, Tao Sun1
1Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Cancer drug resistance (Alhambra, Calif.)
|January 19, 2024
概括
结质母细胞瘤治疗对化疗和免疫疗法的耐药性是一个主要的挑战. 本综述探讨了耐药性的分子机制,为改善质母细胞瘤免疫治疗结果提供了见解.
科学领域:
- 神经瘤学神经瘤学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质母细胞瘤是一种侵袭性的成年原发性脑瘤,自2000年代初以来治疗进展有限.
- 标准的质母细胞瘤治疗包括手术,放射治疗和化疗 (Temozolomide).
- 癌症免疫疗法在其他癌症中取得了成功,但在质母细胞瘤中进展不大.
研究的目的:
- 审查质母细胞瘤中常见的耐药性机制,从Temozolomide到免疫治疗.
- 为抵抗的分子机制提供新的见解,超越已知的挑战,如血脑屏障.
- 建议新的策略来提高质母细胞瘤免疫疗法的疗效.
主要方法:
- 文献综述,重点关注最近的研究.
- 对质母细胞瘤药物耐药性背后的分子机制的分析.
- 关于Temozolomide和免疫疗法耐药性的信息综合.
主要成果:
- 质母细胞瘤表现出复杂的耐药性机制,影响了传统疗法和新型免疫疗法.
- 最近的文献强调了有助于治疗失败的特定分子通路.
- 了解这些机制对于开发有效的治疗策略至关重要.
结论:
- 克服质母细胞瘤的耐药性需要对其分子基础有更深入的了解.
- 针对已识别的抗药性机制可能会改善免疫治疗结果.
- 对新型治疗方法的进一步研究对于推进质母细胞瘤治疗至关重要.
相关概念视频
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


